Ryan E. Wiegand, PhD

Centers for Disease Control and Prevention

Disclosure(s): Merck & Co., Inc.: Stocks/Bonds (Public Company); Sanofi S.A.: Stocks/Bonds (Public Company)

Poster(s):

• (P-1435) Effectiveness of RSV Immunization among Infants in Their First RSV Season in the United States, 2023-2024 and 2024-2025 Seasons
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1436) Respiratory syncytial virus vaccine uptake among Medicare fee-for-service beneficiaries, 2023-2025
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1517) Adult Respiratory Syncytial Virus Vaccination Receipt among Adults Testing Negative for RSV – VISION Network, October 1, 2024—March 31, 2025
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1982) Negative Predictive Value of Methods to Identify Underlying Medical Conditions with and without Use of a Lookback Period among Adults with a Healthcare Encounter for Acute Respiratory Illness, September 2023 – August 2024
  Wednesday, October 22, 2025

  12:15 PM - 1:30 PM US ET